June 10, 2015

MATINAS

BIOPHARMA

Matinas BioPharma to Present at the BIO International Convention on June 18, 2015

BEDMINSTER, N.J., June 10, 2015 (GLOBE NEWSWIRE) --<u>Matinas BioPharma Holdings,</u> Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company, today announced that it will be presenting at the <u>BIO</u> International Convention being held June 15-18, 2015, in Philadelphia, PA.

Roelof Rongen, President and Chief Executive Officer at Matinas BioPharma, will present on Thursday, June 18, 2015, at 10:15 a.m. EDT, in Theater 1 of the Pennsylvania Convention Center.

As part of his presentation, Mr. Rongen will discuss the clinical development strategy for <u>MAT2203</u>, a novel lipid-crystal nano-particle delivered formulation of Amphotericin B for the treatment of invasive fungal infections, and <u>MAT2501</u>, an early-stage program to treat gramnegative bacterial infections.

About the BIO International Convention

The BIO International Convention is considered one of the world's largest, most influential biotech meetings and regularly attracts 15,000 of the most powerful biotech and pharma players from 65 countries, offering powerful business partnering, networking and education that go far beyond professional development. For more information, please visit http://convention.bio.org/.

About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company with a principal focus on identifying and developing novel and targeted pharmaceutical products for the treatment of various infectious diseases, with additional programs developing therapies to treat cardiovascular and metabolic conditions. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas BioPharma is focused on creating highly differentiated, safe and efficacious therapies utilizing its expertise in drug formulation and development in order to address significant unmet medical needs. The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's strategic focus and the future development of its product candidates and

other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

CONTACT: Investor Contact: Jenene Thomas Jenene Thomas Communications, LLC Phone: +1 (908) 938-1475 Email: jthomas@matinasbiopharma.com Media Contact: David Connolly or Silvana Guercilena LaVoieHealthScience Phone: +1 (617) 374-8800 Email: dconnolly@lavoiehealthscience.com / sguercilena@lavoiehealthscience.com

Source: Matinas BioPharma Holdings, Inc.